Cushing’s syndrome is a disease characterized by excess production of cortisol hormone in the blood. It is a severe disease that can be long term and may be life threatening because of the various complications associated with the it such as, diabetes, high blood pressure and mental problems. The common symptoms of the disease include weight gain, roundish face, easy bruising, excessive growth of coarse hair on the face, weakening of the muscles and bones, growth of fat above the collar bone and the back of the neck. The disease is usually caused by a tumor of the pituitary gland (a gland which is situated in the hypothalamus region of the brain) that produces excess amounts of adrenocorticotropic hormone (ACTH), which in turn stimulates the production of excess cortisol from the adrenal glands, which are situated above the kidneys.
CUSHING’S SYNDROME THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
Osilodrostat which is being developed by the Novartis AG is in the Phase III stage of development for the treatment of Cushing’s syndrome. Further companies such as Millendo Therapeutics, Inc., and Corcept Therapeutics Incorporated, have one drug candidate each, in the Phase II stage of development for the treatment of Cushing’s syndrome. Angion Biomedica Corp is in the process of discovery of ANG-3563 for the treatment of Cushing syndrome.
As of November 2017, the Cushing’s syndrome therapeutics pipeline comprises of 13 drug candidates in different stages of development.
Some of the players developing drugs for the treatment of Cushing’s syndrome include Novartis AG, AstraZeneca Plc, Cyclacel Pharmaceuticals, Inc., and Angion Biomedica Corp.